Heart Clinical Trials

At Genesis Heart Institute, you may get an opportunity to enroll in a clinical trial that tests the safety and effectiveness of a new cardiovascular therapy. In the Quad Cities, you’ll find this option only at the Heart Institute because we emphasize innovation so we can better help patients. If you’re interested in a clinical trial, ask your doctor about whether it’s right for you. We’ll help you explore all your treatment possibilities.

Participating in Clinical Trials

To help determine whether you’re eligible for a certain clinical trial, a health care professional will review your medical history. You also may need to receive health screenings, including blood and urine analysis. Your age, sex, previous treatments, type and stage of disease, and other health conditions could affect your eligibility.

If you qualify for a clinical trial, you can choose whether to take part. By enrolling, you’ll gain access to a promising treatment that’s not widely available, and you’ll contribute to medical research that may benefit other patients. But it’s important to remember that your condition may or may not improve during the study. And, like established therapies, new drugs or procedures may cause side effects. The Midwest Cardiovascular Research Foundation and an institutional review board at the Heart Institute monitor the trials to keep you safe and as comfortable as possible. 

Talk to your physician to make sure you fully understand what the clinical trial would involve. Even if you decide to take part, you may leave the study at any time.

Current Heart & Vascular Clinical Trials

Find cardiovascular clinical trials at Genesis that are now enrolling participants.


Synopsis: The APPROPRIATE study will compare differences in functional capacity (peak VO2) between chronotropically incompetent patients randomized to receive rate responsive pacing driven by either the minute ventilation (respiration-based) sensor or an accelerometer (motion based).


Synopsis: The MADIT-CRT trial is designed to determine if combined implantable cardiac defibrillator (ICD)-cardiac resynchronization therapy (CRT-D) will reduce the risk of mortality and heart failure (HF) events by approximately 25%, in subjects who are in New York Heart Association (NYHA) functional Class II with non-ischemic or ischemic cardiomyopathy and subjects who are in NYHA functional Class I with ischemic cardiomyopathy, left ventriuclar dysfunction (ejection fraction [EF] < or = 0.30), and prolonged intraventricular conduction (QRS duration > or = 130 ms).


Synopsis: The purpose of the MADIT-RIT trial is to compare the occurence of inappropriate therapy using high rate cutoff and/or long delay in primary prevention patients receiving and ICD or CRT-D device compared to standard programming.


Synopsis: The objective of this study is to evaluate the safety of vernakalant injection in subjects with recent onset (AF>3 hours too < 7 days), symptomatic atrial fibrillation, and no evidence or history of congestive heart failure (CHF). 

Tailored Treatment of Permanent Atrial Fibrillation (TTOP AF)

Synopsis: The purpose of this study is to evaluate the safety and efficacy of the Ablation Frontiers Cardiac Ablation System compared to currently approved treatment options for atrial fibrillation.


Synopsis: The purpose of this study is to determine if patients in the HeartNet Ventricular Support System with optimal medical and device therapy arm (Treatment group) show statistically significant improvement compared to patients in the optimal medical and device therapy alone arm (Control group) after 6 months of follow-up. 


Synopsis: A randomized multicenter, double blind, group-sequential study to evaluate the efficacy , immunogenicity, and safety of a single dose of Merck 0657nI Staphylococcus Aureus Vaccine (V710) in adult patients scheduled for cardiothoracic surgery.


Synopsis: Heart disease and heart attacks pose a serious health risk to young women, and women tend to experience less successful recoveries after a heart attack than men do. This study will examine various factors that may predispose women to heart attacks and to poor recovery after a heart attack. The differences between men and women in the medical care that they receive following a heart attack will also be studied.

Contact Us

Find out how the Genesis Heart Institute can help you stay well

Call 563-421-3900 or send us your question online.

Related Locations